NEW YORK (TheStreet) -- A San Diego-based biopharmaceutical company is gaining international attention for an experimental Ebola treatment that just saved two lives.
Mapp Biopharmaceutical is that company. Although it might sound like it employs...
Akorn, Inc. (NASDAQ:AKRX)
Q2 2014 Earnings Conference Call
August 5, 2014 10:00 AM ET
Raj Rai - CEO
Tim Dick - CFO
Randall Stanicky - RBC Capital Markets
Traver Davis - Piper Jaffray
David Krempa -...
NEW YORK (TheStreet) -- Shares of Akorn Inc. are up 4.86% to $36 in pre-market trade after the pharmaceutical company won U.S. antitrust approval to buy specialty prescription drug company VersaPharm on condition it sell its rights to a...
Shares of Akorn (NASDAQ: AKRX) were up nearly 10 percent Tuesday around $36.50 following the release of a Needham note in which the price target for the company was raised from $30 to $40.
The note cited a "game changing" effect if Akorn...
MannKind (NASDAQ: MNKD) shares reached a new 52-week high of $11.15 following the Friday's conditional FDA approval for Afrezzaa.
GW Pharmaceuticals plc (NASDAQ: GWPH) reached a new 52-week high of $104.343 as Piper Jaffray raised the price...
Akorn (NASDAQ: AKRX) sold its branded drug unit for $41 million and saw its shares gain nearly four percent Friday morning.
The unit, ECR Pharmaceuticals, went to Valeant Pharmaceuticals (NYSE: VRX) for a combination of $41 million cash and...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Akorn (AKRX):